National Cancer Institute; Notice of Closed Meetings, 53154-53155 [2013-20944]

Download as PDF 53154 Federal Register / Vol. 78, No. 167 / Wednesday, August 28, 2013 / Notices (301) 402–0220; Email: tarak@ mail.nih.gov. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization. This technology relates to the use of glucagon-like peptide–1 (GLP–1), exendin–4, and analogs for the treatment of neurodegenerative diseases. These peptides are GLP–1 receptor agonists and incretin mimetics, and enhance glucose-dependent insulin secretion and regulate glucagon secretion. As such, they have been used in the treatment of type 2 diabetes. The inventors have shown that these peptides also exert neurotrophic and neuroprotective effects in a variety of predictive models of neurodegeneration, and thus may represent potential therapeutics for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), peripheral neuropathy (associated or unassociated with diabetes) and stroke. The prospective Exclusive Patent License may be granted unless the NIH receives written evidence and argument, within thirty (30) days from the date of this published notice, that establishes that the grant of the contemplated license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404. Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the Exclusive Patent License. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. wreier-aviles on DSK5TPTVN1PROD with NOTICES SUPPLEMENTARY INFORMATION: Dated: August 22, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2013–20945 Filed 8–27–13; 8:45 am] BILLING CODE 4140–01–P VerDate Mar<15>2010 15:21 Aug 27, 2013 Jkt 229001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel Detection of Pathogen Induced Cancer. Date: October 1, 2013. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W034, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, MD 20850, 240–276–6368, Stoicaa2@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel Planning for a National Center for Particle Beam Radiation Therapy Research. Date: October 3, 2013. Time: 9:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 6W032, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Thomas A. Winters, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892–9750, 240–276–6386, twinters@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel Informatics Technology for Cancer Research. Date: October 22, 2013. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites-Hotel, 6711 Democracy Blvd., Bethesda, MD 20817. Contact Person: Viatcheslav A Soldatenkov, MD, Ph.D., Scientific Review PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W254, Bethesda, MD 20892– 8329, 240–276–6378, soldatenkovv@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel NCI Omnibus Grants on Cancer Genetics and Etiology. Date: October 22–23, 2013. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites Alexandria—Old Town, 1900 Diagonal Road, Alexandria, VA 22314. Contact Person: Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Bethesda, MD 20892–8329, 240–276–6369, msalin@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group Subcommittee F–Institutional Training and Education. Date: October 28–29, 2013. Time: 7:30 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Arlington Capital View, 2850 South Potomac Avenue, Arlington, VA 22202. Contact Person: Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20850, 240– 276–6464, meekert@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel Research Answers to NCI’s Provocative QuestionsGroup A (R01). Date: October 31–November 1, 2013. Time: 7:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Clifford W Schweinfest, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Bethesda, MD 20892–9750, 240–276–6378, schweinfestcw@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel Collaborative Human Tissue Network (CHTN) (UM1). Date: November 4–5, 2013. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room: Nov 4–6W030 & Nov 5–7W030, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Donald L Coppock, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, E:\FR\FM\28AUN1.SGM 28AUN1 Federal Register / Vol. 78, No. 167 / Wednesday, August 28, 2013 / Notices wreier-aviles on DSK5TPTVN1PROD with NOTICES 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892–9750, 240–276–6382, donald.coppock@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel Small Grants Program for Cancer Epidemiology (R03). Date: November 7, 2013. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Joyce C. Pegues, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, MD 20850, 240–276–6375, peguesj@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel NCI Experimental Therapeutics—Clinical Trials Network with Phase 1 Emphasis. Date: November 12, 2013. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove 9609 Medical Center Drive, Room TE408–410, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20850, 240– 276–6464, meekert@mail.nih.gov. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/irg/irg.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 22, 2013. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–20944 Filed 8–27–13; 8:45 am] BILLING CODE 4140–01–P VerDate Mar<15>2010 15:21 Aug 27, 2013 Jkt 229001 53155 threatened species, unless such a plan would not promote the conservation of Fish and Wildlife Service the species. Section 4(f) of the Act requires that public notice, and an [FWS–R1–ES–2013–N105; opportunity for public review and FXES11130100000C2–134–FF01E00000] comment, be provided during recovery plan development. The draft recovery Endangered and Threatened Wildlife plan for Phyllostegia hispida was and Plants; Recovery Plan for Phyllostegia hispida; Addendum to the published on June 2, 2011, and was available for public comment through Molokai Plant Cluster Recovery Plan August 1, 2011 (76 FR 31973). We have AGENCY: Fish and Wildlife Service, considered information we received Interior. from public comments and peer ACTION: Notice of document availability. reviewers in our preparation of the final recovery plan, and have summarized SUMMARY: We, the U.S. Fish and that information in an appendix of the Wildlife Service, announce the approved recovery plan. We welcome availability of our final recovery plan for continuing public comment on this Phyllostegia hispida (no common name) recovery plan, and we will consider all under the Endangered Species Act of substantive comments on an ongoing 1973, as amended (Act). This plant basis to inform the implementation of species is endemic to the island of recovery activities and future updates to Molokai, Hawaii. This plan is an the recovery plan. We listed Phyllostegia hispida under addendum to the recovery plan for the the Act as an endangered species Molokai Plant Cluster, published in without critical habitat on March 17, September of 1996. The plan includes 2009 (74 FR 11319). Phyllostegia recovery objectives and criteria, and hispida is found only on the island of specific recovery actions necessary to achieve downlisting and delisting of the Molokai. Currently there are less than species and its removal from the Federal 10 wild mature individuals, 3 wild seedlings, and approximately 7 to 10 List of Endangered and Threatened reintroduced individuals on the island Wildlife and Plants. of Molokai. No known population is ADDRESSES: An electronic copy of the entirely protected from the numerous recovery plan is available at https:// factors threatening the species’ recovery, www.fws.gov/endangered/species/ and the species is endangered recovery-plans.html and https:// throughout its range. P. hispida is www.fws.gov/pacific/ecoservices/ endangered/recovery/plans.html. Copies typically found in wet Metrosideros polymorpha (ohia)—dominated forest, of the recovery plan are also available occurring between 1,112 and 1,280 by request from the U.S. Fish and meters (3,650 and 4,200 feet) elevation. Wildlife Service, Pacific Islands Fish The major threats to all known and Wildlife Office, 300 Ala Moana populations are habitat degradation by Boulevard, Room 3–122, Box 50088, feral pigs (Sus scrofa); habitat Honolulu, HI 96850 (telephone: 808– degradation by and competition with 792–9400). invasive introduced plants; predation or FOR FURTHER INFORMATION CONTACT: herbivory by rats (Rattus spp.) and Kristi Young, Deputy Field Supervisor, nonnative slugs; climate change; habitat at the above Honolulu address. degradation by landslides and flooding; SUPPLEMENTARY INFORMATION: and the negative demographic and genetic consequences of extremely small Background population size, as well as the Recovery of endangered or threatened consequent vulnerability to extinction animals and plants is a primary goal of through deterministic or stochastic the Endangered Species Act (Act) (16 (chance) events. Native caterpillar U.S.C. 1531 et seq.) and our endangered species may also pose an herbivory species program. Recovery means threat to this species. improvement of the status of listed The short-term recovery objectives for species to the point at which listing is Phyllostegia hispida focus on stabilizing no longer required under the criteria set all existing populations. To be considered stable, the species must be out in section 4(a)(1) of the Act. managed to control threats (e.g., feral Recovery plans describe actions ungulates and invasive plants) and be considered necessary for the represented in an ex situ population conservation of listed species, establish criteria for downlisting or delisting, and (such as a nursery or arboretum). The estimate time and cost for implementing long-term objectives leading to downlisting and delisting are an the measures needed for recovery. increase in populations and their The Act requires the development of numbers. This increase may require recovery plans for endangered or DEPARTMENT OF THE INTERIOR PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\28AUN1.SGM 28AUN1

Agencies

[Federal Register Volume 78, Number 167 (Wednesday, August 28, 2013)]
[Notices]
[Pages 53154-53155]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20944]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel Detection of Pathogen Induced Cancer.
    Date: October 1, 2013.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 7W034, Rockville, MD 20850, (Telephone Conference 
Call).
    Contact Person: Adriana Stoica, Ph.D., Scientific Review 
Officer, Special Review & Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W234, Rockville, MD 20850, 240-276-6368, 
Stoicaa2@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel Planning for a National Center for Particle Beam Radiation 
Therapy Research.
    Date: October 3, 2013.
    Time: 9:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 6W032, Rockville, MD 20850, (Telephone Conference 
Call).
    Contact Person: Thomas A. Winters, Ph.D., Scientific Review 
Officer, Special Review & Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W412, Bethesda, MD 20892-9750, 240-276-6386, 
twinters@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel Informatics Technology for Cancer Research.
    Date: October 22, 2013.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott Suites-Hotel, 6711 Democracy Blvd., 
Bethesda, MD 20817.
    Contact Person: Viatcheslav A Soldatenkov, MD, Ph.D., Scientific 
Review Officer, Special Review and Logistics Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W254, Bethesda, MD 20892-8329, 240-276-6378, 
soldatenkovv@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel NCI Omnibus Grants on Cancer Genetics and Etiology.
    Date: October 22-23, 2013.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites Alexandria--Old Town, 1900 Diagonal Road, 
Alexandria, VA 22314.
    Contact Person: Marvin L. Salin, Ph.D., Scientific Review 
Officer, Special Review and Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W236, Bethesda, MD 20892-8329, 240-276-6369, 
msalin@mail.nih.gov.

    Name of Committee: National Cancer Institute Initial Review 
Group Subcommittee F-Institutional Training and Education.
    Date: October 28-29, 2013.
    Time: 7:30 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Arlington Capital View, 2850 South Potomac 
Avenue, Arlington, VA 22202.
    Contact Person: Timothy C. Meeker, Ph.D., MD, Scientific Review 
Officer, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W624, Bethesda, MD 20850, 240-276-6464, 
meekert@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel Research Answers to NCI's Provocative Questions-Group A (R01).
    Date: October 31-November 1, 2013.
    Time: 7:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Clifford W Schweinfest, Ph.D., Scientific Review 
Officer, Special Review and Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W108, Bethesda, MD 20892-9750, 240-276-6378, 
schweinfestcw@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel Collaborative Human Tissue Network (CHTN) (UM1).
    Date: November 4-5, 2013.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room: Nov 4-6W030 & Nov 5-7W030, Rockville, MD 20850, 
(Telephone Conference Call).
    Contact Person: Donald L Coppock, Ph.D., Scientific Review 
Officer, Special Review and Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, NIH,

[[Page 53155]]

9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-
276-6382, donald.coppock@nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel Small Grants Program for Cancer Epidemiology (R03).
    Date: November 7, 2013.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Joyce C. Pegues, Ph.D., Scientific Review 
Officer, Special Review and Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W248, Rockville, MD 20850, 240-276-6375, 
peguesj@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel NCI Experimental Therapeutics--Clinical Trials Network with 
Phase 1 Emphasis.
    Date: November 12, 2013.
    Time: 8:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute, Shady Grove 9609 Medical 
Center Drive, Room TE408-410, Rockville, MD 20850, (Telephone 
Conference Call).
    Contact Person: Timothy C. Meeker, Ph.D., MD, Scientific Review 
Officer, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W624, Bethesda, MD 20850, 240-276-6464, 
meekert@mail.nih.gov.

    Information is also available on the Institute's/Center's home 
page: https://deainfo.nci.nih.gov/advisory/irg/irg.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)


    Dated: August 22, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-20944 Filed 8-27-13; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.